

Atty. Dkt. No. IL402US

IFU
\$

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Reed *et al.*

Confirmation No.: 5470

Application No.: 10/823,253

Group Art Unit: 1644

Filed: April 12, 2004

Examiner: Skelding, Zachary

For: RECOMBINANT IL-9 ANTIBODIES AND
USES THEREOF

Attorney Docket No.: IL402US

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form(s) PTO/SB/08, a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 C.F.R. §§ 1.97-1.98.

TIMING OF THE DISCLOSURE

(1) The listed documents are being submitted in compliance with 37 C.F.R. §1.97(d):

Applicants respectfully submit, as provided under 37 C.F.R. §1.97(e)(1), that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicants also authorize the Commissioner to charge the fee set forth in § 1.17(p), and any other fee necessary, for consideration of each item of information disclosed in the information disclosure statement to Deposit Account No. 500479.


(2) Applicants further respectfully submit that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

10/10/2006 JADD01 00000177 500479 10823253
01 FC:1806 180.00 DA

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Respectfully submitted,

Date: October 6, 2006
MEDIMMUNE, INC.
Customer Number: 36577
Telephone: (301) 398-5765
Facsimile: (301) 398-9306

By: 
Michelle Holmes-Son
Registration No. 47,660



PTO/SB/088 (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/823,253
		Filing Date	April 12, 2004
		First Named Inventor	REED, Jennifer
		Art Unit	1644
		Examiner Name	SKELDING, Zachary
Sheet 2	of 2	Attorney Docket Number	IL402US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kung et al., 2001, "Effect of Anti-mIL-9 Antibody on the Development of Pulmonary Inflammation and Airway..." Am. J. Respir. Cell Mol Biol. Vol 25: 600-605.	
		Gruss et al., 1992, "Interleukin 9 Is Expressed By Primary and Cultured Hodgkin and Reed-Sternberg Cells", Cancer Res. 52: 1026-1031.	
		Temann et al. 1998, "Expression of Interleukin 9 in the Lungs of Transgenic Mice Causes Airway..." J. of Experimental Medicine 188(7):1307-1320.	
		Abdelilah et al., 2001, "Functional Expression of IL-9 Receptor by Human Neutrophils from Asthmatic..." Am. Assoc. of Immunologists pp. 2768-2774.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.